Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma

NCT05716087 is registered in ClinicalTrials.gov with Guangzhou Lupeng Pharmaceutical Company LTD. as lead sponsor.

NCT NCT05716087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05716087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma
Lead sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 21, 2023
Completion date
June 30, 2026
Enrollment
62 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)